Study of Association of Arsenic Trioxide (ATO) and Ascorbic Acid in Myelodysplastic Syndromes

Phase 2 Terminated 55 enrolled Fondazione Italiana Sindromi Mielodisplastiche-ETS Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a prospective, multicenter phase II trial designed to evaluate the safety and activity of the combination of association of arsenic trioxide (ATO) and ascorbic acid in patients with myelodysplastic syndromes

Timeline

Start: 2005-09
Primary completion: 2007-01
Completion: 2010-08

Publications

Galimberti S, Guerrini F, Salvi F, Petrini I, Gioia D, Messa E, Palumbo GA, Cilloni D, Petrini M, Levis A. Arsenic trioxide and ascorbic acid interfere with the BCL2 family genes in patients with myelodysplastic syndromes: an ex-vivo study. J Hematol Oncol. 2012 Sep 10;5:53. doi: 10.1186/1756-8722-5-53.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Vitamin C	Other / unclassified	1000 mg	Intravenous
Subject	arsenic trioxide	Small molecule	0.25 mg/kg	Intravenous

Study of Association of Arsenic Trioxide (ATO) and Ascorbic Acid in Myelodysplastic Syndromes

Summary

Timeline

Publications

Drugs

Indications